This new study pure.eur.nl/en/publications... is behind a paywall. I have a copy, it’s not easy to follow but essentially says little T4 crosses the full term placenta from mother to baby but T4 rapidly crosses from baby to mother. The authors suggest this may be a mechanism to protect the baby from maternal thyrotoxicosis (but not Graves’ disease, see later).
Type-3 deiodinase (D3) converts T4 to rT3 and T3 to T2. When D3 was blocked foetal T4 increased. The paper points out that more maternal T4 may be passed to the foetus during earlier stages of pregnancy when placental D3 activity is lower. Many endocrinologists, and a few studies assert that T3 cannot cross the placenta because it is blocked by D3 but the same argument seems to apply to T4 although D3 prefers to act on T3.
I’m not sure these studies are very helpful because they look at free T3 or free T4 and occasionally T3 or T4 bound to specific cellular transporters. In real life T3 and T4 are bound to serum transport proteins with the free components binding to cellular transport proteins in order to cross the placenta. Do any of these in vitro studies reflect what is actually happening?
Studies take donated term placentas, usually full term, a few premature. The baby insists on keeping the placenta until birth!
A bigger and more obvious issue is that in the early stages of pregnancy, when the mother’s hormone levels are crucial, there is no placenta! The placenta starts to function at three to four months. This raises the question of to what extent thyroid hormone transfer from the mother is regulated by the deiodinases and developing placenta.
This pdf download ashfordstpeters.net/Guideli... gives a good description of thyroid hormones during the early stages of development. It also asserts that T3 does not cross the placenta without offering any evidence. It gives detailed advice on the management of babies born to mothers who have had Graves’ disease.
I feel many endocrinologists are unethically creating fear of damaged babies when a mother takes T3. We simply do not know what happens in the early stages of pregnancy, where the baby gets its T3 from. It is wrong to pretend that we understand it. We do know that for over a century hypothyroidism has been teated with NDT and there is no record of harm. It’s possible that NDT therapy will carry a small increased risk compared to levothyroxine monotheapy, or vice-versa. The studies have not been done.
My view is that the obvious default situation is to give T3 and T4 in doses that reflect the healthy population, with different ratios where there is clinical need. It’s interesting to note that a small percentage of endocrinologists who assert T3 cannot cross the placenta will have mothers or grandmothers who were on NDT during pregnancy.